23andMe’s MAP Report Receives FDA’s 510(k) Clearance for Hereditary Colorectal Cancers

  Shots:

• MAP Report is a direct-to-consumer genetic test and has received FDA approval for MUTYH-associated polyposis (MAP), a hereditary colorectal cancer syndrome
• Post-FDA approval for BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in Mar 2018, 23andMe has received its second FDA approval for MAP Report detecting two variants in people with MAP
• The approval allows patients for genetic testing with accurate results & is available for patients with educational module choosing to view their MAP report

Click here to read full press release/ article | Ref: 23andMe | Image: Twitter